RRMS

January 2, 2018January 2, 2018

Gilenya Halts Brain’s Gray Matter Atrophy in RRMS Patients, Study Suggests

News

Treatment with Gilenya (fingolimod) may limit cerebral gray matter atrophy in relapsing-remitting multiple sclerosis (RRMS) patients, researchers at Boston’s Brigham and Women’s Hospital have found. Their report, ... Read more

December 12, 2017December 14, 2017

Using Balloons to Increase Blood Flow from Brain Fails to Help MS Patients, Trial Finds

News

Using balloons to enlarge veins so that more blood flows out of the brain and spinal cord fails to help multiple sclerosis patients, according to a ... Read more

December 11, 2017December 14, 2017

Australia Approves Shorter Mavenclad Treatment Regimen for Relapsing-Remitting MS

News

Australia has approved a shorter treatment regimen of Merck’s Mavenclad for relapsing-remitting multiple sclerosis. The Therapeutic Goods Administration authorized 20-day courses of the cladribine tablet form of the medication once ... Read more

December 6, 2017December 7, 2017

Health Canada Approves Merck’s Mavenclad to Treat RRMS

News

Canadians with relapsing-remitting multiple sclerosis can now receive Merck’s Mavenclad, now that Health Canada has approved Mavenclad as a therapy to reduce the frequency of MS exacerbations and delay ... Read more

November 29, 2017November 30, 2017

Alkermes, Biogen Partnering on Therapy for Relapsing Forms of Multiple Sclerosis

Alexa, News

Alkermes and Biogen have begun working together on a compound known as ALKS 8700 as a potential treatment for relapsing forms of multiple sclerosis. Under the agreement, Alkermes will be responsible ... Read more

November 7, 2017November 7, 2017

Diagnostic Blood Test May Be Able to Distinguish Between RRMS and PPMS, Researchers Say

News

In the future, a blood test may make diagnosing multiple sclerosis (MS) much easier, thanks to newly identified biomarker patterns that distinguish between MS patients and ... Read more

November 3, 2017November 3, 2017

RedHill Awaits US Patent for Antibiotic Combo, RHB-104, as Potential RRMS Therapy

News

RedHill Biopharma has received a Notice of Allowance for a new patent on RHB-104 its potential therapy for patients with relapsing-remitting multiple sclerosis (RRMS). Once granted by the United States ... Read more

October 30, 2017November 3, 2017

#MSParis2017 – Aerobic Exercise Seen to Quickly Strengthen Brain Connections in Patients

News

Aerobic exercise strengthens brain connections in people with relapsing-remitting multiple sclerosis, Jan-Patrick Stellmann, with University Medical Center Hamburg-Eppendorf in Germany, reported at the 7th Joint ECTRIMS-ACTRIMS Meeting ... Read more

September 28, 2017September 28, 2017

Active Brain Inflammation Helps Cause Anxiety, Depression in RRMS Patients, Study Finds

News

Active brain inflammation appears to be one of the causes driving anxiety and depression in patients with relapsing-remitting multiple sclerosis (RRMS), finds an Italian study published ... Read more

September 13, 2017September 14, 2017

Cognitive Impairment Worse Among PPMS Than RRMS Patients, German Study Finds

News

Patients with primary progressive multiple sclerosis have more severe cognitive impairment than those with relapsing-remitting multiple sclerosis, according to a German study that analyzed published data ... Read more

August 31, 2017August 31, 2017

Tecfidera Shows Promise as Replacement MS Therapy for Tysabri, Study Shows

News

Tecfidera (dimethyl fumarate) can be a suitable replacement therapy when Tysabri (natalizumab) is discontinued, keeping low levels of disease activity in patient with relapsing-remitting multiple sclerosis (RRMS), according ... Read more

August 28, 2017August 29, 2017

RRMS Patients Needed for Phase 3 Trial to Assess Adverse GI Effects of ALKS 8700 Therapy vs. Tecfidera

News

Alkermes is funding a Phase 3 clinical trial evaluating the effects of its ALKS 8700 therapy on the gastrointestinal tracts of relapsing-remitting multiple sclerosis (RRMS) patients, compared to Tecfidera (dimethyl fumarate), according ... Read more

August 24, 2017

5 Things to Know About the New MS Drug Ocrevus

The multiple sclerosis community has been waiting with bated breath for the approval of the drug Ocrevus (ocrelizumab), which will be used to treat patients who have relapsing ... Read more

August 17, 2017August 18, 2017

Ocrevus Approved in Canada to Treat Relapsing-Remitting MS

News

Health Canada has approved Ocrevus for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) with active disease, Roche Canada announced. The approval followed the positive results ... Read more

August 3, 2017August 4, 2017

Resistance Training Can Slow MS Patients’ Brain Shrinkage, Clinical Trial Indicates

News

Resistance training like weight lifting can protect or even regenerate the nerve cells of relapsing-remitting multiple sclerosis patients, slowing the progression of the disease, according to ... Read more

July 28, 2017July 28, 2017

Arise Clinics Are Offering Ocrevus to Multiple Sclerosis Patients in Washington Area

News

Five clinics in the Washington area that specialize in administering intravenous and injected treatments to people with chronic diseases are now offering the new multiple sclerosis therapy ... Read more

July 24, 2017July 24, 2017

Study Draws Reverse Link Between Number of a Patient’s MRI Scans a Doctor Checks and Worsened-MS Declarations

News

A new study draws a reverse link between the number of MRI scans of multiple sclerosis patients who are on interferon-beta 1a and doctors declaring there ... Read more

July 17, 2017July 18, 2017

Copaxone Benefits RRMS Patients in the Long Term by Modulating Immune System Responses, Study Shows

News

An Italian study shows that first-line treatment with Copaxone benefits relapsing-remitting multiple sclerosis patients by boosting the number of anti-inflammatory immune cells and restoring the balance ... Read more

July 12, 2017July 13, 2017

Allergy Medicine Fails to Reduce Flu-Like Syndrome in Relapsing-remitting MS Patients, Study Shows

News

According to a new clinical trial, the allergy treatment cetirizine fails to alleviate a flu-like condition that interferon-beta treatment generates in people with relapsing-remitting multiple sclerosis. The ... Read more

June 29, 2017July 2, 2017

Problems with Sense of Smell Are Worse in Primary Progressive MS Than Relapsing-Remitting Form, Study Reports

News

Problems with sense of smell are more frequent and severe in patients with primary progressive multiple sclerosis (PPMS) than in those with relapsing-remitting multiple sclerosis (RRMS), ... Read more

June 27, 2017June 29, 2017

Cladribine Tablets Are Only a Step Away from European Union Approval for Relapsing Multiple Sclerosis

News

Merck’s cladribine tablets are now just one step away from obtaining European Union approval as a relapsing multiple sclerosis treatment. The European Medicines Agency’s Committee for Medicinal ... Read more

June 27, 2017June 27, 2017

Tysabri Shows Long-term Safety, Efficacy in Japanese RRMS Patients, Study Shows

News

A recent study has found Tysabri (natalizumab) treatment for two years to be efficient and safe in Japanese patients with relapsing-remitting multiple sclerosis (RRMS). The study, “Safety and ... Read more

June 21, 2017June 21, 2017

Fatigue and Reduced Leg Function Can Signal Transition to Progressive MS, Study Reports

News

Fatigue and limited leg function are more common among older people with progressive multiple sclerosis than in those with relapsing forms of the disease, according to a ... Read more

June 20, 2017June 26, 2017

Cigarette Smoking Doesn’t Speed Up Disease Progression in PPMS, Canadian Study Suggests

News

Cigarette smoking is certainly no good for you, but it may not necessarily make your primary progressive multiple sclerosis (PPMS) worse, a new study finds. The ... Read more

June 14, 2017June 14, 2017

SPMS Patients Have Higher Illness Burden than RRMS Patients, Kantar Health Study Shows

News

Patients with secondary progressive multiple sclerosis (SPMS) have a higher burden of illness than patients with relapsing-remitting multiple sclerosis, a new study showed. The study, “Characteristics, ... Read more

June 5, 2017June 5, 2017

FDA Approves Two Bayer Products to Help MS Patients Stay on Top of Interferon Injections

News

The U.S. Food and Drug Administration has approved a supplemental biologics license application for two Bayer products that help multiple sclerosis patients keep track of their injections of Betaseron (interferon ... Read more

May 26, 2017May 26, 2017

#CMSC17 – Single Session of Ball-throwing Exercise Improves Balance Control in MS, Study Shows

News

Patients with relapsing-remitting multiple sclerosis (RRMS) regain part of their balance control after a single training session of ball-throwing exercises, finds a study supported by the ... Read more

May 22, 2017October 26, 2017

Real-world Spanish Study Confirms Gilenya’s Ability to Reduce Multiple Sclerosis Relapses

News

A real-world medical-facilities setting has confirmed clinical trial findings that Gilenya (fingolimod) can reduce multiple sclerosis relapses, according to a Spanish study published in Plos One. Gilenya, developed by Novartis ... Read more

May 16, 2017May 16, 2017

RRMS Patients on Beta-Interferon Therapy Have Increased Risk of Stroke, Study Finds

News

A large-scale study revealed potential adverse reactions to beta-interferon (IFN-β) therapy, one of the most common treatments used for relapsing-remitting multiple sclerosis (RRMS). According to the ... Read more

May 9, 2017May 9, 2017

Laquinimod Fails to Meet Primary Clinical Trial Goal of Slowing Progression of RRMS

News

Laquinimod failed to meet its primary Phase 3 clinical trial objective of slowing the progression of relapsing-remitting multiple sclerosis (RRMS) after three months, according to its developers, Teva Pharmaceutical ... Read more

May 4, 2017May 4, 2017

Cladribine Tablets Reduce Risk of MS Progression and Relapse, Clinical Trial Shows

News

Cladribine tablets reduce the risk of disability progression and relapse in patients with relapsing multiple sclerosis (MS), the CLARITY clinical trial indicates. The treatment was also ... Read more

April 21, 2017April 21, 2017

Decisions to Stop Taking Tysabri for MS Are Often Subjective, Study Concludes

News

Many decisions to stop taking the multiple sclerosis treatment Tysabri (natalizumab) appear to be based largely on subjective factors such as patients’ or physicians’ view of the risk, ... Read more

April 20, 2017April 20, 2017

Early Use of Tecfidera and Tysabri Improves MS Patients’ Outcomes, Studies Suggest

News

The latest results on Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) use in a clinical practice setting suggest that early treatment can improve outcomes in multiple sclerosis (MS) ... Read more

April 20, 2017April 20, 2017

Teva to Discuss MS and Huntington’s Therapies at Premier Neurology Conference

News

Teva Pharmaceutical Industries will discuss two of its multiple sclerosis therapies, one that reduces relapses and one that appears to protect nerve structure, at a premier ... Read more

April 18, 2017April 18, 2017

Norwegian Researchers Analyze MS Life Expectancy, Survival and Mortality in 60-year Longitudinal Study

News

A 60-year longitudinal multiple sclerosis (MS) study in a Norwegian cohort analyzing life expectancy, survival and mortality concluded that MS patients live shorter lives and have ... Read more

April 13, 2017April 13, 2017

Scottish Medicines Consortium Approves Zinbryta for NHS Treatment of RRMS Patients in Scotland

News

  The United Kingdom’s National Institute for Health and Care Excellence (NICE) last month recommended Zinbryta (daclizumab) to treat relapsing-remitting multiple sclerosis (RRMS) in England and Wales. On April 10, Scotland received Scottish Medicines ... Read more

April 12, 2017April 13, 2017

Ocrevus Approval: A Quick Cheat Sheet

The multiple sclerosis (MS) community has been busy talking about the recently FDA-approved drug Ocrevus (ocrelizumab). It’s been proven to slow down the progression of the disease, but ... Read more

April 12, 2017April 13, 2017

5 Things to Know About the New MS Drug Ocrevus

BREAKING NEWS: FDA Approves Ocrevus as 1st MS Treatment for Both Relapsing and Primary Progressive Forms The multiple sclerosis community has been waiting with bated breath for ... Read more

March 25, 2017March 29, 2017

5 Things to Know About the New MS Drug Ocrevus

BREAKING NEWS: FDA Approves Ocrevus as 1st MS Treatment for Both Relapsing and Primary Progressive Forms The multiple sclerosis community has been waiting with bated breath for ... Read more

March 20, 2017March 20, 2017

Alkermes Begins Phase 3 Study of ALKS 8700 as Relapsing MS Treatment

News

Alkermes has started a Phase 3 clinical trial evaluating ALKS 8700, the oral monomethyl fumarate (MMF) prodrug it is developing for the treatment of relapsing forms of ... Read more